Evommune, Inc.EVMN
Price (close)
$8.80
Market cap
—
P/E
—
Revenue (TTM)
$10.0M
Net income
-$94.7M
Dividend yield
—
1-year total return
—
Net margin
-946.7%
Revenue growth
—
Debt / equity
—
What Evommune, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | — | $7.0M | $13.0M |
| Net income | — | -$66.8M | -$68.9M |
| Free cash flow | — | -$58.3M | -$76.7M |
More on EVMN.
- Evommune, Inc. summary
- Evommune, Inc. financial statements
- Evommune, Inc. key metrics
- Evommune, Inc. health scores and style box
- Evommune, Inc. earnings
- Evommune, Inc. dividends
- Evommune, Inc. valuation
- Evommune, Inc. ownership and insiders
- Evommune, Inc. peers
Figures from Evommune, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.